Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
> 26 27 26 27 O
= 27 28 27 28 O
1,500 29 34 29 34 B-lower_bound
/ 34 35 34 35 I-lower_bound
mm^3 35 39 35 39 I-lower_bound

Any 0 3 40 43 O
patient 4 11 44 51 O
requiring 12 21 52 61 O
chronic 22 29 62 69 O
maintenance 30 41 70 81 O
of 42 44 82 84 O
white 45 50 85 90 B-clinical_variable
blood 51 56 91 96 I-clinical_variable
cell 57 61 97 101 I-clinical_variable
counts 62 68 102 108 I-clinical_variable
or 69 71 109 111 O
granulocyte 72 83 112 123 B-clinical_variable
counts 84 90 124 130 I-clinical_variable
through 91 98 131 138 O
the 99 102 139 142 O
use 103 106 143 146 O
of 107 109 147 149 O
growth 110 116 150 156 O
factor 117 123 157 163 O
support 124 131 164 171 O
( 132 133 172 173 O
e.g. 133 137 173 177 O
Neulasta 138 146 178 186 B-treatment
, 146 147 186 187 O
Neupogen 148 156 188 196 B-treatment
) 156 157 196 197 O

Aspartate 0 9 198 207 B-clinical_variable
aminotransferase 10 26 208 224 I-clinical_variable
( 27 28 225 226 I-clinical_variable
AST 28 31 226 229 I-clinical_variable
) 31 32 229 230 I-clinical_variable
( 33 34 231 232 O
serum 34 39 232 237 B-clinical_variable
glutamic 40 48 238 246 I-clinical_variable
oxaloacetic 49 60 247 258 I-clinical_variable
transaminase 61 73 259 271 I-clinical_variable
[ 74 75 272 273 I-clinical_variable
SGOT])/alanine 75 89 273 287 I-clinical_variable
aminotransferase 90 106 288 304 I-clinical_variable
( 107 108 305 306 I-clinical_variable
ALT 108 111 306 309 I-clinical_variable
) 111 112 309 310 I-clinical_variable
( 113 114 311 312 O
serum 114 119 312 317 B-clinical_variable
glutamate 120 129 318 327 I-clinical_variable
pyruvate 130 138 328 336 I-clinical_variable
transaminase 139 151 337 349 I-clinical_variable
[ 152 153 350 351 I-clinical_variable
SGPT 153 157 351 355 I-clinical_variable
] 157 158 355 356 I-clinical_variable
) 158 159 356 357 O
= 160 161 358 359 O
< 161 162 359 360 O
2.5 163 166 361 364 B-upper_bound
times 167 172 365 370 I-upper_bound
the 173 176 371 374 I-upper_bound
institutional 177 190 375 388 I-upper_bound
upper 191 196 389 394 I-upper_bound
limit 197 202 395 400 I-upper_bound
of 203 205 401 403 I-upper_bound
normal 206 212 404 410 I-upper_bound

Creatinine 0 10 411 421 B-clinical_variable
= 11 12 422 423 O
< 12 13 423 424 O
1.5 14 17 425 428 B-clinical_variable
times 18 23 429 434 I-clinical_variable
institutional 24 37 435 448 B-clinical_variable
upper 38 43 449 454 I-clinical_variable
limit 44 49 455 460 I-clinical_variable
of 50 52 461 463 I-clinical_variable
normal 53 59 464 470 I-clinical_variable
or 60 62 471 473 O
creatinine 63 73 474 484 B-clinical_variable
clearance 74 83 485 494 I-clinical_variable
> 84 85 495 496 O
= 85 86 496 497 O
60 87 89 498 500 B-lower_bound
mL 90 92 501 503 I-lower_bound
/ 92 93 503 504 I-lower_bound
min/1.73 93 101 504 512 I-lower_bound
m^2 102 105 513 516 I-lower_bound

Eastern 0 7 517 524 B-clinical_variable
Cooperative 8 19 525 536 I-clinical_variable
Oncology 20 28 537 545 I-clinical_variable
Group 29 34 546 551 I-clinical_variable
( 35 36 552 553 I-clinical_variable
ECOG 36 40 553 557 I-clinical_variable
) 40 41 557 558 I-clinical_variable
performance 42 53 559 570 I-clinical_variable
status 54 60 571 577 I-clinical_variable
= 61 62 578 579 O
< 62 63 579 580 O
2 64 65 581 582 B-upper_bound

Eligible 0 8 583 591 O
patients 9 17 592 600 O
in 18 20 601 603 O
the 21 24 604 607 O
dose 25 29 608 612 O
escalation 30 40 613 623 O
phases 41 47 624 630 O
of 48 50 631 633 O
the 51 54 634 637 O
trial 55 60 638 643 O
must 61 65 644 648 O
agree 66 71 649 654 O
to 72 74 655 657 O
biopsies 75 83 658 666 B-treatment
of 84 86 667 669 O
normal 87 93 670 676 O
skin 94 98 677 681 O
, 98 99 681 682 O
unless 100 106 683 689 O
they 107 111 690 694 O
undergo 112 119 695 702 O
optional 120 128 703 711 O
tumor 129 134 712 717 B-treatment
biopsies 135 143 718 726 I-treatment
; 143 144 726 727 O
the 145 148 728 731 O
mandatory 149 158 732 741 O
biopsy 159 165 742 748 B-treatment
requirement 166 177 749 760 O
can 178 181 761 764 O
be 182 184 765 767 O
waived 185 191 768 774 O
at 192 194 775 777 O
the 195 198 778 781 O
discretion 199 209 782 792 O
of 210 212 793 795 O
principal 213 222 796 805 O
investigator 223 235 806 818 O
in 236 238 819 821 O
the 239 242 822 825 O
event 243 248 826 831 O
of 249 251 832 834 O
any 252 255 835 838 O
medical 256 263 839 846 O
contraindication 264 280 847 863 O
( 281 282 864 865 O
e.g. 282 286 865 869 O
lidocaine 287 296 870 879 B-allergy_name
allergy 297 304 880 887 O
) 304 305 887 888 O
; 305 306 888 889 O
patients 307 315 890 898 O
enrolled 316 324 899 907 O
to 325 327 908 910 O
the 328 331 911 914 O
expanded 332 340 915 923 O
cohorts 341 348 924 931 O
must 349 353 932 936 O
agree 354 359 937 942 O
to 360 362 943 945 O
tumor 363 368 946 951 O
sampling 369 377 952 960 O
; 377 378 960 961 O
patients 379 387 962 970 O
on 388 390 971 973 O
anticoagulation 391 406 974 989 B-treatment
must 407 411 990 994 O
be 412 414 995 997 O
able 415 419 998 1002 O
to 420 422 1003 1005 O
hold 423 427 1006 1010 O
warfarin 428 436 1011 1019 B-treatment
or 437 439 1020 1022 O
low 440 443 1023 1026 B-treatment
molecular 444 453 1027 1036 I-treatment
weight 454 460 1037 1043 I-treatment
heparin 461 468 1044 1051 I-treatment
for 469 472 1052 1055 O
a 473 474 1056 1057 O
sufficient 475 485 1058 1068 O
amount 486 492 1069 1075 O
of 493 495 1076 1078 O
time 496 500 1079 1083 O
to 501 503 1084 1086 O
make 504 508 1087 1091 O
skin 509 513 1092 1096 B-treatment
and 514 517 1097 1100 I-treatment
tumor 518 523 1101 1106 I-treatment
biopsies 524 532 1107 1115 I-treatment
safe 533 537 1116 1120 O
to 538 540 1121 1123 O
perform 541 548 1124 1131 O
; 548 549 1131 1132 O
PT 550 552 1133 1135 B-clinical_variable
/ 552 553 1135 1136 O
INR 553 556 1136 1139 B-clinical_variable
and 557 560 1140 1143 O
PTT 561 564 1144 1147 B-clinical_variable
should 565 571 1148 1154 O
be 572 574 1155 1157 O
= 575 576 1158 1159 O
< 576 577 1159 1160 O
1.5 578 581 1161 1164 B-upper_bound
times 582 587 1165 1170 I-upper_bound
the 588 591 1171 1174 I-upper_bound
institutional 592 605 1175 1188 I-upper_bound
upper 606 611 1189 1194 I-upper_bound
limit 612 617 1195 1200 I-upper_bound
of 618 620 1201 1203 I-upper_bound
normal 621 627 1204 1210 I-upper_bound
prior 628 633 1211 1216 O
to 634 636 1217 1219 O
performance 637 648 1220 1231 O
of 649 651 1232 1234 O
skin 652 656 1235 1239 B-treatment
or 657 659 1240 1242 I-treatment
tumor 660 665 1243 1248 I-treatment
biopsies 666 674 1249 1257 I-treatment
, 674 675 1257 1258 O
with 676 680 1259 1263 O
values 681 687 1264 1270 O
re 688 690 1271 1273 O
- 690 691 1273 1274 O
checked 691 698 1274 1281 O
after 699 704 1282 1287 O
the 705 708 1288 1291 O
eligibility 709 720 1292 1303 O
screen 721 727 1304 1310 O
as 728 730 1311 1313 O
medically 731 740 1314 1323 O
indicated 741 750 1324 1333 O

Hemoglobin 0 10 1334 1344 B-clinical_variable
( 11 12 1345 1346 I-clinical_variable
Hgb 12 15 1346 1349 I-clinical_variable
) 15 16 1349 1350 I-clinical_variable
> 17 18 1351 1352 O
10.0 19 23 1353 1357 B-lower_bound
g 24 25 1358 1359 I-lower_bound
/ 25 26 1359 1360 I-lower_bound
dL 26 28 1360 1362 I-lower_bound
with 29 33 1363 1367 O
no 34 36 1368 1370 O
blood 37 42 1371 1376 B-treatment
transfusion 43 54 1377 1388 I-treatment
in 55 57 1389 1391 O
the 58 61 1392 1395 O
past 62 66 1396 1400 B-upper_bound
28 67 69 1401 1403 I-upper_bound
day 70 73 1404 1407 I-upper_bound

Participants 0 12 1408 1420 O
must 13 17 1421 1425 O
have 18 22 1426 1430 O
histologically 23 37 1431 1445 O
confirmed 38 47 1446 1455 O
diagnosis 48 57 1456 1465 O
of 58 60 1466 1468 O
a 61 62 1469 1470 O
solid 63 68 1471 1476 B-cancer
tumor 69 74 1477 1482 I-cancer
for 75 78 1483 1486 O
which 79 84 1487 1492 O
no 85 87 1493 1495 O
curative 88 96 1496 1504 B-treatment
therapy 97 104 1505 1512 I-treatment
exists 105 111 1513 1519 O

Patients 0 8 1520 1528 O
enrolling 9 18 1529 1538 O
in 19 21 1539 1541 O
the 22 25 1542 1545 O
BRCA 26 30 1546 1550 B-clinical_variable
- 30 31 1550 1551 O
deficient 31 40 1551 1560 O
cohorts 41 48 1561 1568 O
must 49 53 1569 1573 O
have 54 58 1574 1578 O
a 59 60 1579 1580 O
documented 61 71 1581 1591 O
BRCA1 72 77 1592 1597 B-clinical_variable
or 78 80 1598 1600 O
BRCA2 81 86 1601 1606 B-clinical_variable
germline 87 95 1607 1615 O
mutation 96 104 1616 1624 O
; 104 105 1624 1625 O
alternatively 106 119 1626 1639 O
, 119 120 1639 1640 O
patients 121 129 1641 1649 O
with 130 134 1650 1654 O
tumors 135 141 1655 1661 O
harboring 142 151 1662 1671 O
somatic 152 159 1672 1679 O
BRCA 160 164 1680 1684 O
mutations 165 174 1685 1694 O
may 175 178 1695 1698 O
also 179 183 1699 1703 O
enroll 184 190 1704 1710 O
after 191 196 1711 1716 O
discussion 197 207 1717 1727 O
with 208 212 1728 1732 O
the 213 216 1733 1736 O
principal 217 226 1737 1746 O
investigator 227 239 1747 1759 O

Patients 0 8 1760 1768 O
must 9 13 1769 1773 O
not 14 17 1774 1777 O
receive 18 25 1778 1785 O
any 26 29 1786 1789 O
other 30 35 1790 1795 O
anti 36 40 1796 1800 B-treatment
- 40 41 1800 1801 I-treatment
cancer 41 47 1801 1807 I-treatment
therapy 48 55 1808 1815 I-treatment
( 56 57 1816 1817 O
cytotoxic 57 66 1817 1826 B-treatment
, 66 67 1826 1827 O
biologic 68 76 1828 1836 B-treatment
, 76 77 1836 1837 O
radiation 78 87 1838 1847 B-treatment
, 87 88 1847 1848 O
or 89 91 1849 1851 O
hormonal 92 100 1852 1860 B-treatment
other 101 106 1861 1866 O
than 107 111 1867 1871 O
for 112 115 1872 1875 O
replacement 116 127 1876 1887 O
) 127 128 1887 1888 O
while 129 134 1889 1894 O
on 135 137 1895 1897 O
this 138 142 1898 1902 O
study 143 148 1903 1908 O
except 149 155 1909 1915 O
for 156 159 1916 1919 O
medications 160 171 1920 1931 B-treatment
that 172 176 1932 1936 O
are 177 180 1937 1940 O
prescribed 181 191 1941 1951 O
for 192 195 1952 1955 O
supportive 196 206 1956 1966 B-treatment
care 207 211 1967 1971 I-treatment
but 212 215 1972 1975 O
may 216 219 1976 1979 O
potentially 220 231 1980 1991 O
have 232 236 1992 1996 O
an 237 239 1997 1999 O
anti 240 244 2000 2004 O
- 244 245 2004 2005 O
cancer 245 251 2005 2011 O
effect 252 258 2012 2018 O
( 259 260 2019 2020 O
i.e. 260 264 2020 2024 O
megestrol 265 274 2025 2034 B-treatment
acetate 275 282 2035 2042 I-treatment
, 282 283 2042 2043 O
bisphosphonates 284 299 2044 2059 B-treatment
) 299 300 2059 2060 O
; 300 301 2060 2061 O
in 302 304 2062 2064 O
addition 305 313 2065 2073 O
, 313 314 2073 2074 O
men 315 318 2075 2078 O
receiving 319 328 2079 2088 O
treatment 329 338 2089 2098 B-treatment
for 339 342 2099 2102 O
prostate 343 351 2103 2111 B-cancer
cancer 352 358 2112 2118 I-cancer
will 359 363 2119 2123 O
be 364 366 2124 2126 O
maintained 367 377 2127 2137 O
at 378 380 2138 2140 O
castrate 381 389 2141 2149 O
levels 390 396 2150 2156 O
of 397 399 2157 2159 O
testosterone 400 412 2160 2172 B-clinical_variable
by 413 415 2173 2175 O
continuation 416 428 2176 2188 O
of 429 431 2189 2191 O
luteinizing 432 443 2192 2203 B-treatment
- 443 444 2203 2204 I-treatment
releasing 444 453 2204 2213 I-treatment
hormone 454 461 2214 2221 I-treatment
agonists 462 470 2222 2230 I-treatment
; 470 471 2230 2231 O
palliative 472 482 2232 2242 B-treatment
radiation 483 492 2243 2252 I-treatment
therapy 493 500 2253 2260 I-treatment
( 501 502 2261 2262 I-treatment
XRT 502 505 2262 2265 I-treatment
) 505 506 2265 2266 I-treatment
can 507 510 2267 2270 O
be 511 513 2271 2273 O
administered 514 526 2274 2286 O
on 527 529 2287 2289 O
study 530 535 2290 2295 O
after 536 541 2296 2301 O
documented 542 552 2302 2312 O
discussion 553 563 2313 2323 O
with 564 568 2324 2328 O
the 569 572 2329 2332 O
principal 573 582 2333 2342 O
investigator 583 595 2343 2355 O
; 595 596 2355 2356 O
for 597 600 2357 2360 O
patients 601 609 2361 2369 O
in 610 612 2370 2372 O
expansion 613 622 2373 2382 O
cohorts 623 630 2383 2390 O
, 630 631 2390 2391 O
this 632 636 2392 2396 O
must 637 641 2397 2401 O
not 642 645 2402 2405 O
involve 646 653 2406 2413 O
target 654 660 2414 2420 O
lesions 661 668 2421 2428 O

Patients 0 8 2429 2437 O
who 9 12 2438 2441 O
have 13 17 2442 2446 O
previously 18 28 2447 2457 O
received 29 37 2458 2466 O
SCH727965 38 47 2467 2476 B-treatment

Patients 0 8 2477 2485 O
with 9 13 2486 2490 O
known 14 19 2491 2496 O
active 20 26 2497 2503 O
brain 27 32 2504 2509 B-cancer
metastases 33 43 2510 2520 I-cancer

Patients 0 8 2521 2529 O
with 9 13 2530 2534 O
other 14 19 2535 2540 O
medical 20 27 2541 2548 O
conditions 28 38 2549 2559 O
judged 39 45 2560 2566 O
by 46 48 2567 2569 O
the 49 52 2570 2573 O
investigator 53 65 2574 2586 O
to 66 68 2587 2589 O
be 69 71 2590 2592 O
clinically 72 82 2593 2603 O
relevant 83 91 2604 2612 O
in 92 94 2613 2615 O
the 95 98 2616 2619 O
setting 99 106 2620 2627 O
of 107 109 2628 2630 O
this 110 114 2631 2635 O
study 115 120 2636 2641 O
, 120 121 2641 2642 O
which 122 127 2643 2648 O
may 128 131 2649 2652 O
include 132 139 2653 2660 O
active 140 146 2661 2667 O
infectious 147 157 2668 2678 O
processes 158 167 2679 2688 O
, 167 168 2688 2689 O
intractable 169 180 2690 2701 B-chronic_disease
emesis 181 187 2702 2708 I-chronic_disease
, 187 188 2708 2709 O
or 189 191 2710 2712 O
chronic 192 199 2713 2720 O
diarrheal 200 209 2721 2730 B-chronic_disease
disease 210 217 2731 2738 I-chronic_disease

Patients 0 8 2739 2747 O
with 9 13 2748 2752 O
prior 14 19 2753 2758 O
seizure 20 27 2759 2766 B-chronic_disease
history 28 35 2767 2774 O
who 36 39 2775 2778 O
have 40 44 2779 2783 O
experienced 45 56 2784 2795 O
a 57 58 2796 2797 O
seizure 59 66 2798 2805 O
within 67 73 2806 2812 O
the 74 77 2813 2816 O
three 78 83 2817 2822 B-upper_bound
months 84 90 2823 2829 I-upper_bound
prior 91 96 2830 2835 I-upper_bound
to 97 99 2836 2838 O
enrollment 100 110 2839 2849 O

Platelets 0 9 2850 2859 B-clinical_variable
> 10 11 2860 2861 O
= 11 12 2861 2862 O
100,000 13 20 2863 2870 B-lower_bound
/ 20 21 2870 2871 I-lower_bound
mm^3 21 25 2871 2875 I-lower_bound

Pregnant 0 8 2876 2884 B-pregnancy
women 9 14 2885 2890 B-gender
are 15 18 2891 2894 O
excluded 19 27 2895 2903 O
from 28 32 2904 2908 O
this 33 37 2909 2913 O
study 38 43 2914 2919 O
because 44 51 2920 2927 O
ABT-888 52 59 2928 2935 B-treatment
and 60 63 2936 2939 O
SCH727965 64 73 2940 2949 B-treatment
are 74 77 2950 2953 O
anti 78 82 2954 2958 B-treatment
- 82 83 2958 2959 I-treatment
proliferative 83 96 2959 2972 I-treatment
agents 97 103 2973 2979 I-treatment
with 104 108 2980 2984 O
the 109 112 2985 2988 O
potential 113 122 2989 2998 O
for 123 126 2999 3002 O
teratogenic 127 138 3003 3014 O
or 139 141 3015 3017 O
abortifacient 142 155 3018 3031 O
effects 156 163 3032 3039 O
; 163 164 3039 3040 O
because 165 172 3041 3048 O
there 173 178 3049 3054 O
is 179 181 3055 3057 O
an 182 184 3058 3060 O
unknown 185 192 3061 3068 O
but 193 196 3069 3072 O
potential 197 206 3073 3082 O
risk 207 211 3083 3087 O
of 212 214 3088 3090 O
adverse 215 222 3091 3098 O
events 223 229 3099 3105 O
in 230 232 3106 3108 O
nursing 233 240 3109 3116 O
infants 241 248 3117 3124 O
secondary 249 258 3125 3134 O
to 259 261 3135 3137 O
treatment 262 271 3138 3147 B-treatment
of 272 274 3148 3150 O
the 275 278 3151 3154 O
mother 279 285 3155 3161 O
with 286 290 3162 3166 O
ABT-888 291 298 3167 3174 O
and 299 302 3175 3178 O
SCH727965 303 312 3179 3188 O
, 312 313 3188 3189 O
breastfeeding 314 327 3190 3203 O
should 328 334 3204 3210 O
be 335 337 3211 3213 O
discontinued 338 350 3214 3226 O
if 351 353 3227 3229 O
the 354 357 3230 3233 O
mother 358 364 3234 3240 O
is 365 367 3241 3243 O
treated 368 375 3244 3251 O
with 376 380 3252 3256 O
ABT-888 381 388 3257 3264 O
and 389 392 3265 3268 O
SCH727965 393 402 3269 3278 O
; 402 403 3278 3279 O
these 404 409 3280 3285 O
potential 410 419 3286 3295 O
risks 420 425 3296 3301 O
may 426 429 3302 3305 O
also 430 434 3306 3310 O
apply 435 440 3311 3316 O
to 441 443 3317 3319 O
other 444 449 3320 3325 O
agents 450 456 3326 3332 O
used 457 461 3333 3337 O
in 462 464 3338 3340 O
this 465 469 3341 3345 O
study 470 475 3346 3351 O

Prior 0 5 3352 3357 B-treatment
allogeneic 6 16 3358 3368 I-treatment
bone 17 21 3369 3373 I-treatment
marrow 22 28 3374 3380 I-treatment
transplant 29 39 3381 3391 I-treatment
or 40 42 3392 3394 O
double 43 49 3395 3401 B-treatment
umbilical 50 59 3402 3411 I-treatment
cord 60 64 3412 3416 I-treatment
blood 65 70 3417 3422 I-treatment
transplantation 71 86 3423 3438 I-treatment

Prior 0 5 3439 3444 O
chemotherapy 6 18 3445 3457 B-treatment

Prior 0 5 3458 3463 B-treatment
experimental 6 18 3464 3476 I-treatment
( 19 20 3477 3478 I-treatment
non 20 23 3478 3481 I-treatment
- 23 24 3481 3482 I-treatment
Food 24 28 3482 3486 I-treatment
and 29 32 3487 3490 I-treatment
Drug 33 37 3491 3495 I-treatment
Administration 38 52 3496 3510 I-treatment
[ 53 54 3511 3512 I-treatment
FDA 54 57 3512 3515 I-treatment
] 57 58 3515 3516 I-treatment
approved 59 67 3517 3525 I-treatment
) 67 68 3525 3526 I-treatment
therapies 69 78 3527 3536 I-treatment
and 79 82 3537 3540 O
immunotherapies 83 98 3541 3556 B-treatment

Prior 0 5 3557 3562 O
exposure 6 14 3563 3571 O
to 15 17 3572 3574 O
ABT888 18 24 3575 3581 B-treatment
or 25 27 3582 3584 O
other 28 33 3585 3590 O
PARP 34 38 3591 3595 B-treatment
inhibitors 39 49 3596 3606 I-treatment
is 50 52 3607 3609 O
permitted 53 62 3610 3619 O
in 63 65 3620 3622 O
all 66 69 3623 3626 O
cohorts 70 77 3627 3634 O

Prior 0 5 3635 3640 O
exposure 6 14 3641 3649 O
to 15 17 3650 3652 O
approved 18 26 3653 3661 O
receptor 27 35 3662 3670 O
tyrosine 36 44 3671 3679 B-treatment
kinase 45 51 3680 3686 I-treatment
inhibitors 52 62 3687 3697 I-treatment
is 63 65 3698 3700 O
permitted 66 75 3701 3710 O
; 75 76 3710 3711 O
at 77 79 3712 3714 O
least 80 85 3715 3720 O
5 86 87 3721 3722 B-lower_bound
half 88 92 3723 3727 O
- 92 93 3727 3728 O
lives 93 98 3728 3733 O
must 99 103 3734 3738 O
have 104 108 3739 3743 O
elapsed 109 116 3744 3751 O
since 117 122 3752 3757 O
the 123 126 3758 3761 O
completion 127 137 3762 3772 O
of 138 140 3773 3775 O
the 141 144 3776 3779 O
kinase 145 151 3780 3786 O
inhibitor 152 161 3787 3796 O
and 162 165 3797 3800 O
the 166 169 3801 3804 O
initiation 170 180 3805 3815 O
of 181 183 3816 3818 O
study 184 189 3819 3824 O
treatment 190 199 3825 3834 B-treatment

Prior 0 5 3835 3840 B-treatment
radiation 6 15 3841 3850 I-treatment
therapy 16 23 3851 3858 I-treatment

Prothrombin 0 11 3859 3870 B-clinical_variable
time 12 16 3871 3875 I-clinical_variable
( 17 18 3876 3877 I-clinical_variable
PT)/international 18 35 3877 3894 I-clinical_variable
normalized 36 46 3895 3905 I-clinical_variable
ratio 47 52 3906 3911 I-clinical_variable
( 53 54 3912 3913 I-clinical_variable
INR 54 57 3913 3916 I-clinical_variable
) 57 58 3916 3917 I-clinical_variable
and 59 62 3918 3921 O
partial 63 70 3922 3929 B-clinical_variable
thromboplastin 71 85 3930 3944 I-clinical_variable
time 86 90 3945 3949 I-clinical_variable
( 91 92 3950 3951 I-clinical_variable
PTT 92 95 3951 3954 I-clinical_variable
) 95 96 3954 3955 I-clinical_variable
= 97 98 3956 3957 O
< 98 99 3957 3958 O
1.5 100 103 3959 3962 B-upper_bound
times 104 109 3963 3968 I-upper_bound
institutional 110 123 3969 3982 I-upper_bound
upper 124 129 3983 3988 I-upper_bound
limit 130 135 3989 3994 I-upper_bound
of 136 138 3995 3997 I-upper_bound
normal 139 145 3998 4004 I-upper_bound

Subjects 0 8 4005 4013 O
on 9 11 4014 4016 O
a 12 13 4017 4018 O
potent 14 20 4019 4025 O
CYP3A4 21 27 4026 4032 B-treatment
inhibitor 28 37 4033 4042 I-treatment
or 38 40 4043 4045 O
CPY3A4 41 47 4046 4052 B-treatment
inducer 48 55 4053 4060 I-treatment
who 56 59 4061 4064 O
can 60 63 4065 4068 O
not 63 66 4068 4071 O
be 67 69 4072 4074 O
changed 70 77 4075 4082 O
to 78 80 4083 4085 O
another 81 88 4086 4093 O
medication 89 99 4094 4104 B-treatment

Subjects 0 8 4105 4113 O
with 9 13 4114 4118 O
a 14 15 4119 4120 O
known 16 21 4121 4126 O
allergy 22 29 4127 4134 O
to 30 32 4135 4137 O
lidocaine 33 42 4138 4147 B-allergy_name

Subjects 0 8 4148 4156 O
with 9 13 4157 4161 O
treatment 14 23 4162 4171 O
- 23 24 4171 4172 O
related 24 31 4172 4179 O
acute 32 37 4180 4185 B-cancer
myeloid 38 45 4186 4193 I-cancer
leukemia 46 54 4194 4202 I-cancer
( 55 56 4203 4204 I-cancer
AML 56 59 4204 4207 I-cancer
) 59 60 4207 4208 I-cancer
( 61 62 4209 4210 O
t 62 63 4210 4211 B-cancer
- 63 64 4211 4212 I-cancer
AML)/myelodysplastic 64 84 4212 4232 I-cancer
syndrome 85 93 4233 4241 I-cancer
( 94 95 4242 4243 I-cancer
MDS 95 98 4243 4246 I-cancer
) 98 99 4246 4247 I-cancer
or 100 102 4248 4250 O
with 103 107 4251 4255 O
features 108 116 4256 4264 O
suggestive 117 127 4265 4275 O
of 128 130 4276 4278 O
AML 131 134 4279 4282 O
/ 134 135 4282 4283 O
MDS 135 138 4283 4286 O

The 0 3 4287 4290 O
effects 4 11 4291 4298 O
of 12 14 4299 4301 O
ABT-888 15 22 4302 4309 B-treatment
and 23 26 4310 4313 O
SCH727965 27 36 4314 4323 B-treatment
on 37 39 4324 4326 O
the 40 43 4327 4330 O
developing 44 54 4331 4341 O
human 55 60 4342 4347 O
fetus 61 66 4348 4353 O
are 67 70 4354 4357 O
unknown 71 78 4358 4365 O
; 78 79 4365 4366 O
for 80 83 4367 4370 O
this 84 88 4371 4375 O
reason 89 95 4376 4382 O
, 95 96 4382 4383 O
women 97 102 4384 4389 B-gender
of 103 105 4390 4392 O
childbearing 106 118 4393 4405 O
potential 119 128 4406 4415 O
and 129 132 4416 4419 O
men 133 136 4420 4423 O
must 137 141 4424 4428 O
agree 142 147 4429 4434 B-contraception_consent
to 148 150 4435 4437 I-contraception_consent
use 151 154 4438 4441 I-contraception_consent
adequate 155 163 4442 4450 I-contraception_consent
contraception 164 177 4451 4464 I-contraception_consent
( 178 179 4465 4466 O
hormonal 179 187 4466 4474 B-contraception_consent
or 188 190 4475 4477 I-contraception_consent
barrier 191 198 4478 4485 I-contraception_consent
method 199 205 4486 4492 I-contraception_consent
of 206 208 4493 4495 I-contraception_consent
birth 209 214 4496 4501 I-contraception_consent
control 215 222 4502 4509 I-contraception_consent
; 222 223 4509 4510 O
abstinence 224 234 4511 4521 B-contraception_consent
) 234 235 4521 4522 O
prior 236 241 4523 4528 O
to 242 244 4529 4531 O
study 245 250 4532 4537 O
entry 251 256 4538 4543 O
and 257 260 4544 4547 O
for 261 264 4548 4551 O
the 265 268 4552 4555 O
duration 269 277 4556 4564 O
of 278 280 4565 4567 O
study 281 286 4568 4573 O
participation 287 300 4574 4587 O

Total 0 5 4588 4593 O
bilirubin 6 15 4594 4603 B-clinical_variable
< 16 17 4604 4605 O
1.5 18 21 4606 4609 B-upper_bound
mg 22 24 4610 4612 I-upper_bound
/ 24 25 4612 4613 I-upper_bound
dl 25 27 4613 4615 I-upper_bound

Uncontrolled 0 12 4616 4628 O
intercurrent 13 25 4629 4641 B-chronic_disease
illness 26 33 4642 4649 I-chronic_disease
including 34 43 4650 4659 O
, 43 44 4659 4660 O
but 45 48 4661 4664 O
not 49 52 4665 4668 O
limited 53 60 4669 4676 O
to 61 63 4677 4679 O
ongoing 64 71 4680 4687 O
or 72 74 4688 4690 O
active 75 81 4691 4697 B-chronic_disease
infection 82 91 4698 4707 I-chronic_disease
, 91 92 4707 4708 O
symptomatic 93 104 4709 4720 O
congestive 105 115 4721 4731 B-chronic_disease
heart 116 121 4732 4737 I-chronic_disease
failure 122 129 4738 4745 I-chronic_disease
, 129 130 4745 4746 O
unstable 131 139 4747 4755 B-chronic_disease
angina 140 146 4756 4762 I-chronic_disease
pectoris 147 155 4763 4771 I-chronic_disease
, 155 156 4771 4772 O
or 157 159 4773 4775 O
psychiatric 160 171 4776 4787 B-chronic_disease
illness 172 179 4788 4795 I-chronic_disease
/ 179 180 4795 4796 I-chronic_disease
social 180 186 4796 4802 I-chronic_disease
situations 187 197 4803 4813 I-chronic_disease
that 198 202 4814 4818 O
would 203 208 4819 4824 O
limit 209 214 4825 4830 O
compliance 215 225 4831 4841 O
with 226 230 4842 4846 O
study 231 236 4847 4852 O
requirements 237 249 4853 4865 O

patients 0 8 4866 4874 O
may 9 12 4875 4878 O
not 13 16 4879 4882 O
have 17 21 4883 4887 O
areas 22 27 4888 4893 O
of 28 30 4894 4896 O
irradiated 31 41 4897 4907 B-clinical_variable
marrow 42 48 4908 4914 I-clinical_variable
exceeding 49 58 4915 4924 O
40 59 61 4925 4927 B-lower_bound
% 61 62 4927 4928 I-lower_bound
of 63 65 4929 4931 O
bone 66 70 4932 4936 B-clinical_variable
marrow 71 77 4937 4943 I-clinical_variable
volume 78 84 4944 4950 I-clinical_variable

patients 0 8 4951 4959 O
must 9 13 4960 4964 O
not 14 17 4965 4968 O
have 18 22 4969 4973 O
had 23 26 4974 4977 O
nitrosoureas 27 39 4978 4990 B-treatment
or 40 42 4991 4993 O
mitomycin 43 52 4994 5003 B-treatment
C 53 54 5004 5005 I-treatment
for 55 58 5006 5009 O
6 59 60 5010 5011 B-upper_bound
weeks 61 66 5012 5017 I-upper_bound
prior 67 72 5018 5023 I-upper_bound
to 73 75 5024 5026 O
the 76 79 5027 5030 O
initiation 80 90 5031 5041 O
of 91 93 5042 5044 O
study 94 99 5045 5050 B-treatment
treatment 100 109 5051 5060 I-treatment

patients 0 8 5061 5069 O
must 9 13 5070 5074 O
not 14 17 5075 5078 O
have 18 22 5079 5083 O
received 23 31 5084 5092 O
any 32 35 5093 5096 O
radiation 36 45 5097 5106 B-treatment
within 46 52 5107 5113 O
3 53 54 5114 5115 B-upper_bound
weeks 55 60 5116 5121 I-upper_bound
prior 61 66 5122 5127 I-upper_bound
to 67 69 5128 5130 O
the 70 73 5131 5134 O
initiation 74 84 5135 5145 O
of 85 87 5146 5148 O
study 88 93 5149 5154 O
treatment 94 103 5155 5164 O

patients 0 8 5165 5173 O
must 9 13 5174 5178 O
not 14 17 5179 5182 O
have 18 22 5183 5187 O
received 23 31 5188 5196 O
chemotherapy 32 44 5197 5209 B-treatment
for 45 48 5210 5213 O
3 49 50 5214 5215 B-upper_bound
weeks 51 56 5216 5221 I-upper_bound
prior 57 62 5222 5227 I-upper_bound
to 63 65 5228 5230 O
the 66 69 5231 5234 O
initiation 70 80 5235 5245 O
of 81 83 5246 5248 O
study 84 89 5249 5254 O
treatment 90 99 5255 5264 B-treatment
and 100 103 5265 5268 O
must 104 108 5269 5273 O
have 109 113 5274 5278 O
full 114 118 5279 5283 O
recovery 119 127 5284 5292 O
from 128 132 5293 5297 O
any 133 136 5298 5301 O
acute 137 142 5302 5307 O
effects 143 150 5308 5315 O
of 151 153 5316 5318 O
any 154 157 5319 5322 O
prior 158 163 5323 5328 B-treatment
chemotherapy 164 176 5329 5341 I-treatment

patients 0 8 5342 5350 O
must 9 13 5351 5355 O
not 14 17 5356 5359 O
have 18 22 5360 5364 O
received 23 31 5365 5373 O
these 32 37 5374 5379 O
therapies 38 47 5380 5389 B-treatment
for 48 51 5390 5393 O
3 52 53 5394 5395 B-upper_bound
weeks 54 59 5396 5401 I-upper_bound
prior 60 65 5402 5407 I-upper_bound
to 66 68 5408 5410 O
the 69 72 5411 5414 O
initiation 73 83 5415 5425 O
of 84 86 5426 5428 O
study 87 92 5429 5434 B-treatment
treatment 93 102 5435 5444 I-treatment
and 103 106 5445 5448 O
must 107 111 5449 5453 O
have 112 116 5454 5458 O
full 117 121 5459 5463 O
recovery 122 130 5464 5472 O
from 131 135 5473 5477 O
any 136 139 5478 5481 O
acute 140 145 5482 5487 O
effects 146 153 5488 5495 O
of 154 156 5496 5498 O
these 157 162 5499 5504 O
therapies 163 172 5505 5514 O

patients 0 8 5515 5523 O
with 9 13 5524 5528 O
a 14 15 5529 5530 O
history 16 23 5531 5538 O
of 24 26 5539 5541 O
central 27 34 5542 5549 B-cancer
nervous 35 42 5550 5557 I-cancer
system 43 49 5558 5564 I-cancer
( 50 51 5565 5566 I-cancer
CNS 51 54 5566 5569 I-cancer
) 54 55 5569 5570 I-cancer
metastases 56 66 5571 5581 I-cancer
that 67 71 5582 5586 O
have 72 76 5587 5591 O
been 77 81 5592 5596 O
treated 82 89 5597 5604 O
must 90 94 5605 5609 O
be 95 97 5610 5612 O
stable 98 104 5613 5619 O
with 105 109 5620 5624 O
no 110 112 5625 5627 O
symptoms 113 121 5628 5636 O
for 122 125 5637 5640 O
> 126 127 5641 5642 O
3 128 129 5643 5644 B-lower_bound
months 130 136 5645 5651 I-lower_bound
after 137 142 5652 5657 O
completion 143 153 5658 5668 O
of 154 156 5669 5671 O
that 157 161 5672 5676 O
treatment 162 171 5677 5686 B-treatment
and 172 175 5687 5690 O
off 176 179 5691 5694 O
steroid 180 187 5695 5702 B-treatment
treatment 188 197 5703 5712 I-treatment
, 197 198 5712 5713 O
with 199 203 5714 5718 O
image 204 209 5719 5724 O
documentation 210 223 5725 5738 O
required 224 232 5739 5747 O
prior 233 238 5748 5753 O
to 239 241 5754 5756 O
study 242 247 5757 5762 O
enrollment 248 258 5763 5773 O

prior 0 5 5774 5779 O
exposure 6 14 5780 5788 O
to 15 17 5789 5791 O
cyclin 18 24 5792 5798 B-treatment
- 24 25 5798 5799 I-treatment
dependent 25 34 5799 5808 I-treatment
kinase 35 41 5809 5815 I-treatment
inhibitors 42 52 5816 5826 I-treatment
other 53 58 5827 5832 O
than 59 63 5833 5837 O
SCH727965 64 73 5838 5847 B-treatment
is 74 76 5848 5850 O
permitted 77 86 5851 5860 O

subjects 0 8 5861 5869 O
with 9 13 5870 5874 O
known 14 19 5875 5880 O
liver 20 25 5881 5886 B-cancer
metastases 26 36 5887 5897 I-cancer
, 36 37 5897 5898 O
AST 38 41 5899 5902 B-clinical_variable
and 42 45 5903 5906 O
ALT 46 49 5907 5910 B-clinical_variable
= 50 51 5911 5912 O
< 51 52 5912 5913 O
5 53 54 5914 5915 B-upper_bound
times 55 60 5916 5921 I-upper_bound
institutional 61 74 5922 5935 I-upper_bound
upper 75 80 5936 5941 I-upper_bound
limit 81 86 5942 5947 I-upper_bound
of 87 89 5948 5950 I-upper_bound
normal 90 96 5951 5957 I-upper_bound

